Judge refuses to block pay-for-delay law pending appeal
13-01-2020
casimiropt / Shutterstock.com
Buyers of AbbVie’s arthritis treatment Humira (adalimumab) have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, antitrust, competition, licensing deals, patent thickets, Pfizer, Sandoz, Mylan, biosimilars, Seventh Circuit